Because TFRC is overexpressed in a variety of human tumors, antibodies targeting TFRC are attractive and straightforward therapeutic options.[14] However, the safety of this type of treatment is a major concern, as many normal tissues like bone marrow and lymphoid tissues express high levels of TFRC.[16] In contrast, the FDA‐approved iron chelator DFO has a relatively safe record in the clinical treatment of iron overload diseases. The gene discussed is TFRC; the disease is Rare hereditary hemochromatosis.